Quotient Sciences has launched a Phase I clinical trial for a novel drug product, developed using artificial intelligence (AI), marking a potential breakthrough in AI-driven drug formulation.
The trial, conducted at Quotient Sciences' UK facility, has received approval from the MHRA and aims to assess the safety and pharmacokinetics of the drug in healthy volunteers. This initiative is significant as it seeks to validate AI's role in drug development, potentially enhancing formulation design and decision-making processes. Quotient Sciences claims this is the first instance of an AI-designed formulation undergoing clinical evaluation.
Andy Lewis, Chief Scientific Officer at Quotient Sciences, emphasized that this program represents a key advancement in the integration of machine learning with scientific expertise, aimed at streamlining the drug development process. This synergy is expected to empower clients to make more informed decisions earlier, thereby improving the chances of clinical success.
The study utilizes Intrepid Labs' machine learning algorithms to facilitate formulation design and optimization, enabling quicker exploration of options and data-driven decisions. This milestone aligns with Quotient Sciences’ strategy to incorporate AI across its formulation development and clinical workflows. The company plans to provide further updates on its AI initiatives in the coming months, indicating a commitment to advancing capabilities in this innovative area.